A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
Hervé Bonnefoi(Université de Bordeaux), Thomas Grellety(Université de Bordeaux), Olivier Trédan(Centre Léon Bérard), Mahasti Saghatchian(Institut Gustave Roussy), Florence Dalenc(Institut Claudius Regaud), Audrey Mailliez(Centre Oscar Lambret), T. L'Haridon(Roche (Switzerland)), Paul Cottu(Université Paris Sciences et Lettres), Sophie Abadie‐Lacourtoisie, Benoît You(Lyon College), M Mousseau(Centre Hospitalier Universitaire de Grenoble), Jérôme Dauba, Francesco Del Piano, Isabelle Desmoulins(Centre Georges François Leclerc), Florence Coussy(Institut Curie), Nicolas Madranges(Université de Bordeaux), Julien Grenier(Institut Sainte Catherine), François‐Clément Bidard(Université Paris Sciences et Lettres), Charlotte Proudhon(Université Paris Sciences et Lettres), Gaëtan MacGrogan(Inserm), C. Orsini(UniCancer Group), M. Pulido(Inserm), Anthony Gonçalves(Centre National de la Recherche Scientifique)
Cited by 281Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis